Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

ession is responsible for the majority of deaths. The two year loco-regional failure rate following front line treatment is around 30% with a further 20% of patients progressing at a distant site. The long-term loco-regional control rate of 100% combined with the high percentage of patients that remain disease free at up to 40 months from treatment is very encouraging and provides confidence that OncoVEX (GM-CSF) will significantly reduce relapse rates as compared to standard therapy alone in the pivotal study recently agreed with the FDA."

About Head and Neck Cancer

Head and neck cancer accounts for 47,000 new cases (3% of all new cancer cases and 2% of all cancer deaths) in the United States annually; it is the fifth most common malignancy worldwide (an estimated 644,000 new cases annually).

Patients with locally advanced tumors are best treated with concurrent chemoradiation, with planned neck dissection indicated in certain patients. Despite aggressive treatment of locally advanced disease loco-regional recurrences develop in 30% of patients and distant metastases in 20%. Aggressive combined modality therapy may be frequently associated with debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX (GM-CSF) is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX (GM-CSF) designed to work by; repli
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... DALLAS , July 10, 2014  Kainos Capital, ... consumer brands, today announced that it has acquired the ... stake in the business. Terms of the transaction were ... loss and meal replacement business that markets ready-to-drink shakes, ... North America and in the ...
(Date:7/10/2014)... WASHINGTON D.C., April 15, 2014 -- According to ... danger to nuclear security comes from terrorists acquiring ... (HEU) to construct a crude nuclear explosive device. ... illicit nuclear trafficking have involved gram-level quantities, which ... methods. , According to a new study appearing ...
(Date:7/10/2014)... has been extremely challenging because there are many genetic ... cause disease. Now investigators reporting in the July 3rd ... Cell describe a strategy that may help reveal ... factors or environmental exposures to affect the development of ... that may predispose individuals to schizophrenia. , The ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... 18 Joseph F. Finn, Jr., C.P.A. ("Finn"), announced ... respiratory indication will be part of the intellectual property offered ... , The PRX-08066 is a Therapeutics Program ... small molecule, oral 5HT2b antagonist for potential treatment of pulmonary ...
... ... been selected by Prometheus as the sample collection kit for MyCeliacID™ a saliva-based genetic ... service as it solves sample collection challenges inherent with traditional collection methods which are ... ...
... CANTON, Mass., Aug. 18 Small and large companies ... stay profitable in this economy. EquipNet is announcing an amazing ... and packaging equipment from a leading pharmaceutical manufacturer. A webcast ... August 27 at 11am. Enthusiastic bargain hunters can make pre-sale ...
Cached Biology Technology:Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 3Pre-Owned Prices on Premium Pharmaceutical Equipment 2
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric ... CEO Mr. Gino Pereira was interviewed on July ... Tampa Florida . Mr. Pereira discusses the ... Cedric Harris and how the Wocket™ aims to replace ... Cedric Harris tells Gino he has ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4
... deepens customer relationships, WALL, N.J., Aug. 15 ... leader in wireless public safety and,finger-based biometric identification ... quarter ended June 30, 2007. Total revenue ... 30, 2007 decreased 19% to $2.5 million from ...
... Nature Methods Shows Application of Bioinformatics tools to ... ... Aug. 21 Researchers at Selexis SA,and The University ... Elements also known as matrix attachment regions,(or MARs). Data ...
... of interesting new compounds have been discovered inside the bodies ... September 2007) at the Society for General Microbiologys 161st Meeting ... September 2007. Over half of the bodyweight of living ... our baths is made up of the many different ...
Cached Biology News:BIO-key Reports Second Quarter 2007 Results 2BIO-key Reports Second Quarter 2007 Results 3BIO-key Reports Second Quarter 2007 Results 4BIO-key Reports Second Quarter 2007 Results 5Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines 2Bacteria from sponges make new pharmaceuticals 2
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
...
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Biology Products: